Atezolizumab Plus Bevacizumab Alone or Combined with External Beam Radiotherapy for HCC with Macrovascular Invasion

PHASE2RecruitingINTERVENTIONAL
Enrollment

138

Participants

Timeline

Start Date

October 22, 2022

Primary Completion Date

March 31, 2026

Study Completion Date

March 31, 2026

Conditions
Hepatocellular CarcinomaHepatocellular CancerHepatocellular Carcinoma Non-resectableHepatocellular Carcinoma Stage IVLiver Cancer
Interventions
RADIATION

Atezolizumab plus bevacizumab, combined EBRT to vascular invasion

"The external beam radiotherapy will commence after day 2 of the first cycle of atezolizumab+bevacizumab, and will be delivered in accordance with institutional protocol.~3D-conformal radiotherapy technique is used to determine target volumes, radiation ports, and dose prescriptions by using a 3D radiotherapy planning system.~The gross tumor volume (GTV) includes vascular invasion and a 2-cm margin into the contiguous HCC. The GTV can consist of the entire HCC and vascular invasion at the discretion of the investigator.~The target dose is 45 Gy, however, the total dose can be reduced as low as 30 Gy according to the liver function, liver volumes, or the maximum dose to the stomach/duodenum during the planning process according to the judgment of the radiation oncologist of each participating sites."

DRUG

Atezolizumab plus bevacizumab

Atezolizumab plus bevacizumab q3w

Trial Locations (1)

Unknown

RECRUITING

Asan Medical Center, Seoul

Sponsors
All Listed Sponsors
collaborator

Seoul National University Hospital

OTHER

collaborator

Hanyang University

OTHER

collaborator

Soon Chun Hyang University

OTHER

lead

Asan Medical Center

OTHER